MARKET WIREYahoo Finance • 1d ago
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst RevisionsYahoo Finance report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
Why IMMX Stock dropped -5.47% Today — RQD Quant Desk Flash
$7.26 -5.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.17
Immix Biopharma Inc. (IMMX) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $636.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IMMX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IMMX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Immix Biopharma Inc. (NASDAQ: IMMX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.26 (-5.47% 1D, market cap $636.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMMX ranks #823 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IMMX compare to LXRX and ABUS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXRX (Lexicon Pharmaceuticals Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -31.5%, cap $631.8M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $645.3M). Among the 5-stock peer group, IMMX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IMMX?
▼
Per IMMX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001873835), Immix Biopharma Inc. generated $83.9M in revenue (+32.1% YoY), -$29.4M in net income, and -$24.7M in free cash flow against $104.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.18 (-1.17%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMMX)Realized 20D OHLCV Swing Band: ±12.2%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY IMMX SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$8.69+2.5% Next Q
37
Q2 (-2Q)Grade E$8.91-9.7% Next Q
34
Q3 (-1Q)Grade E$8.05-9.8% Next Q
32
CurrentGrade E$7.26-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMMX Turnaround Squeeze
While IMMX currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.79) and Max Pain ($7.62) forces dealer call-delta covering toward $15.86.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMMX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMMX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMMX Stock dropped -5.47% Today — RQD Quant Desk Flash
Immix Biopharma Inc. (IMMX) dropped -5.47% to $7.26, trading at 36% of its 52-week range ($2.85 – $15.1). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 36% of its 52-week range ($2.85 – $15.1) with RSI-14 at 32.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.2% around $7.26 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IMMX Headlines & Catalysts
MARKET WIREInvesting.com • 1d ago
Morgan Stanley initiates Immix Biopharma stock with overweight ratingInvesting.com report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Immix Biopharma, Inc. Estimates – NASDAQ:IMMXTradingView report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall Street • 1d ago
Immix Biopharma (NasdaqCM:IMMX) Stock PriceSimply Wall Street report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
BlackRock reports a passive stake above 5% in Immix Biopharma (IMMX).Stock Titan report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 1d ago
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?TradingView report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMMX)
- ✓Walkthrough of IMMX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMMX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.42%▼ SUPPORT BREAKDOWN
2026-11-03O $7.98H $7.98L $7.26C $7.26VOL 1.38M
RES: $18.05SUP: $7.59SMA50: $10.79SMA200: $9.51
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMMX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +32.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on IMMX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMMX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMMX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMMX)
Health Care Rank #823 of 1015
⚔️ LXRX vs IMMX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMMX vs. LXRX, ABUS, ANL, OLMA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Immix Biopharma Inc. (IMMX) ranks #823 by composite RQD confidence (29/100, grade E) and #406 by equity capitalization ($636.7M). Within this direct 5-issuer industry benchmark cohort, IMMX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with IMMX at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMMX
ACTIVE
Immix Biopharma Inc. | E | 29/100 | — | — | -35.0% | -5.47% | $636.7M | Benchmark Subject |
| LXRX Lexicon Pharmaceuticals Inc. | E | 26/100 | — | 96.0% | -31.5% | +1.41% | $631.8M | /lxrx-vs-immx → |
| ABUS Arbutus Biopharma Corporation | E | 18/100 | — | — | -35.0% | -4.99% | $645.3M | /abus-vs-immx → |
| ANL Adlai Nortye Group Ltd. | D | 46/100 | — | — | — | -1.88% | $615.0M | /anl-vs-immx → |
| OLMA Olema Pharmaceuticals Inc. | E | 29/100 | — | — | -32.8% | +1.00% | $612.5M | /olma-vs-immx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001873835 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immix Biopharma Inc. (IMMX) reported GAAP revenue of $83.9M (+32.1% vs. FY2024 revenue of $63.5M , and +85.6% cumulative change since FY2023) , GAAP net income of -$29.4M, operating cash flow of -$23.9M, and free cash flow of -$24.7M (-56.4% YoY). On the balance sheet, IMMX closed FY2025 with $104.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $83.9M | -$29.4M | -$23.9M | -$24.7M | $104.8M | — |
| FY2024 (FY) | 2024-12-31 | $63.5M | -$21.6M | -$14.6M | -$15.8M | $22.9M | — |
| FY2023 (FY) | 2023-12-31 | $45.2M | -$15.4M | -$11.4M | -$11.4M | — | — |
3. IMMX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMMX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Immix Biopharma Inc. (NASDAQ: IMMX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.26 (-5.47% 1D, market cap $636.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IMMX ranks #823 in composite RQD confidence.
How does IMMX compare to LXRX and ABUS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXRX (Lexicon Pharmaceuticals Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -31.5%, cap $631.8M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $645.3M). Among the 5-stock peer group, IMMX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMMX?
Per IMMX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001873835), Immix Biopharma Inc. generated $83.9M in revenue (+32.1% YoY), -$29.4M in net income, and -$24.7M in free cash flow against $104.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMMX trading relative to its 50-day, 200-day, and 52-week technical levels?
IMMX last traded at $7.26 (-5.47% on volume of 1,507,101 shares), positioning the stock -32.72% below its 50-day simple moving average ($10.79) and -23.66% below its 200-day simple moving average ($9.51). Across its 52-week range of $2.85 to $15.10, IMMX sits at the 36.0% percentile with a 14-day RSI of 32.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.2% ($6.37 to $8.15).
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ SEC XBRL & RQD VERIFIED
IMMX — Immix Biopharma Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Immix Biopharma Inc. (IMMX) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $7.26 (-5.47% 1D, market capitalization $636.7M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -3.73%.
- Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Immix Biopharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..7B. — describes its products, customers, or revenue model. The reported revenue of — across the FY 2023–FY 2025 periods indicates no revenue generation in those years .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Immix Biopharma Inc. (IMMX) reported $83.9M in annual revenue (up from $63.5M in FY2024, +32.1% YoY) and -$29.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($45.2M revenue, -$15.4M net income) through FY2025, IMMX scaled operating cash flow to -$23.9M and free cash flow to -$24.7M, backed by $104.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.73% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $2.85 – $15.10 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations.
- Key Question #1: Can IMMX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $83.9M and free cash flow of -$24.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is IMMX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
IMMX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Immix Biopharma Inc. (IMMX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
Immix Biopharma (IMMX) Stock Sees Modest Fair Value Lift After Split Analyst Revisions Yahoo Finance report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Morgan Stanley initiates Immix Biopharma stock with overweight rating Investing.com report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Immix Biopharma, Inc. Estimates – NASDAQ:IMMX TradingView report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall Street • 1d ago
Immix Biopharma (NasdaqCM:IMMX) Stock Price Simply Wall Street report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference GlobeNewswire report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
BlackRock reports a passive stake above 5% in Immix Biopharma (IMMX). Stock Titan report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength? TradingView report covering Immix Biopharma Inc. (IMMX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IMMX Bull vs. Bear Conversation Board — What's Your Call at $7.26?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMMX 🐻 33% BEARISH CONVICTION
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH
🎯 Target: $9.22 (+20.1%)
📌 Pinned Debate Reported cash rose to $93.9M in FY 2025 from $17.7M in FY 2024, and Morgan Stanley initiated coverage with an overweight rating.
Long IMMX at $7.68 targeting $9.22. Reported cash rose to $93.9M in FY 2025 from $17.7M in FY 2024, and Morgan Stanley initiated coverage with an overweight rating.. Institutional whale score is 4/20 and the risk/reward vs. the $2.85 52-week low is skewed heavily in favor of bulls.
SectorRotator 🐂 BULL
@BreakoutHunter Agree on the RQD 29/100 quality, though with 1.0 beta I'm scaling in with half-size at $7.68 and keeping dry powder in case we test $7.14.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $6.07 (-21.0%)
Spot @ $7.68 The company reports zero revenue across FY 2023–FY 2025, operating losses widened to -$30.0M, and the RQD rating is a Strong Sell at 29
Sitting on the sidelines or leaning short IMMX above $7.68. The company reports zero revenue across FY 2023–FY 2025, operating losses widened to -$30.0M, and the RQD rating is a Strong Sell at 29/100.. Until Fundamental Cash Engine (6/20) and FCF yield (-3.73%) inflect higher, upside is capped near $15.10.